Good morning. Elizabeth Cooney here today, filling in for Ed Silverman. In his spirit, I will remind you that we have made it this far through the work week, so shall we carry on? He might also wonder if we have any choice. While you ponder whether to get all existential, here are some news items to get you going.

As Puma Biotechnology (PBYI) struggles to meet sales goals and expand usage for its all-important Nerlynx breast cancer treatment, the company has resorted to a tried-and-true tactic for boosting sales — raising prices, STAT writes. But Puma has taken a step most other drug makers have avoided recently: The wholesale price for Nerlynx not only jumped twice this year, but by 9.9% each time, for a total increase of 20% in just nine months.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy